RT Journal Article
T1 RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
A1 Torrente-Segarra, Vicenc
A1 Urruticoechea Arana, Ana
A1 Sanchez-Andrade Fernandez, Amalia
A1 Tovar Beltran, Juan Victor
A1 Munoz Jimenez, Alejandro
A1 Martinez-Cristobal, Anna
A1 Gonzalez Ferrandez, Jose Antonio
A1 Fernandez Prada, Manuel
A1 Vazquez Fuentes, Noelia
A1 Corominas, Hector
A1 Garcia-Diaz, Silvia
A1 Acosta Pereira, Asuncion
A1 Ruiz Martin, Jose Miguel
A1 Lamua Riazuelo, Jose Ramon
A1 Exposito Moliner, Rosa
A1 Ruiz Vilchez, Desiree
A1 Veiga Cabello, Raul
A1 Carlos Fernandez, Jesus
A1 Noguera Pons, Jose Raul
A1 Garrido Punal, Noemi Patricia
A1 Giralt Celimendiz, Pedro
A1 Cortes Verdu, Raul
A1 Aragon Diez, Angel
A1 Tomas Roura, Carlos
A1 Moll Turudi, Concepcion
A1 Taverner Torrent, Delia
A1 Rivas Santirso, Felipe Joaquin
A1 Lerma Garrido, Juan Jose
A1 Garcia Portales, Rosa
A1 Ordonez Palau, Sergi
A1 Paredes Gonzalez-Albo, Silvia
A1 Gracia Perez, Antonio
A1 Conesa Mateos, Arantxa
A1 Calvo Alen, Jaime
A1 Grana Gil, Jenaro
A1 Navarro Alonso, Maria Pilar
A1 Martinez Blasco, Maria Jesus
A1 RENACER StudyGrp, 
K1 Certolizumab PEGol
K1 Clinical practice
K1 Efficacy
K1 Rheumatoid arthritis
K1 Safety
K1 Spanish population
K1 Survival rate
K1 College-of-rheumatology
K1 Danish danbio registry
K1 Anti-tnf therapy
K1 Clinical-practice
K1 Long-term
K1 Plus methotrexate
K1 Japanese patients
K1 Gisea registry
K1 Alpha agents
K1 Adalimumab
AB Objective: To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Methods: Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.Results: We included 168 patients: 79.2% women, mean age 54.5 years (+/- 13.2 SD), mean disease duration 7.5 years (+/- 7.3 SD). Mean number of prior DMARD: 1.4 (+/- 1.2 SD), mean number of prior BT was 0.8 (+/- 1.1). Mean time on CZP was 9.8 months (+/- 3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p
PB Springer
SN 1439-7595
YR 2016
FD 2016-01-01
LK http://hdl.handle.net/10668/19206
UL http://hdl.handle.net/10668/19206
LA en
DS RISalud
RD Apr 11, 2025